Skip to main content
  • Register
  • Help
  • Contact us
  • Log out of your HL account

Surface Oncology Inc (SURF) USD0.0001

Sell:$1.75 Buy:$1.77 Change: $0.04 (2.21%)
Market closed |  Prices as at close on 13 December 2019 | Switch to live prices |
Sell:$1.75
Buy:$1.77
Change: $0.04 (2.21%)
Market closed |  Prices as at close on 13 December 2019 | Switch to live prices |
Sell:$1.75
Buy:$1.77
Change: $0.04 (2.21%)
Market closed |  Prices as at close on 13 December 2019 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Surface Oncology, Inc. is a clinical-stage immuno-oncology company. The Company is engaged in the development of cancer immunotherapies. To unlock the potential of cancer immunotherapy, the Company is targeting a set of immune processes by which cancer cells evade immune recognition and attack. Its programs are built upon insights about how to improve the immune system’s recognition and elimination of cancer cells. These include approaches to improve the effectiveness of antigen presentation to the adaptive immune system, to block the activity of a range of suppressor cells in the tumor microenvironment, and to counter the immunosuppressive environment that selectively accumulates in and around the tumor. By targeting the interface of innate and adaptive immunity, it hopes to expand the reach of cancer immunotherapy to patients in need of treatment.

Contact details

Address:
50 Hampshire St Fl 8
CAMBRIDGE
02139-1548
United States
Telephone:
+1 (617) 7144096
Website:
https://www.surfaceoncology.com/

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
SURF
ISIN:
US86877M2098
Market cap:
$51.30 million
Shares in issue:
27.88 million
Sector:
Biotechnology
Exchange:
NASDAQ
Country:
United States
Currency:
US dollar
Indices:
n/a

Key personnel

  • Daniel Lynch
    Executive Chairman of the Board
  • J. Jeffrey Goater
    President, Chief Executive Officer, Director
  • Jessica Fees
    Principal Financial Officer, Principal Accounting Officer, Senior Vice President, Finance and Business Operations and Treasurer
  • Vito Palombella
    Chief Scientific Officer
  • Liisa Nogelo
    General Counsel, Secretary
  • Wendy Dwyer
    Chief Business Officer
  • Robert Ross
    Chief Medical Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.